120 results about "Degenerative disease" patented technology

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.

The application discloses a magnetic therapy mattress convex structure for cervical and lumbar vertebra regions and relates to the technical field of magnetic therapy mattresses. The magnetic therapy mattress convex structure comprises an outer frame and a mattress convex assembly assembled on the inner side of the outer frame. The mattress convex assembly comprises two groups of eccentric transmission wheel structures arranged oppositely, the eccentric transmission wheel structures generate wave arc motion with continuous undulation, and a plurality of spring magnet composite units are arranged on the eccentric transmission wheel structures. Each group of the spring magnet composite units is further provided with a convex module simulating a spinal process. The wave arc motion with continuous undulation generated by the eccentric transmission wheel structure can match the physiological curvature of the cervical and lumbar vertebrae of the human body, and can effectively prevent or improve the degenerative diseases of the cervical and lumbar vertebrae. Meanwhile, the spring magnet composite units are designed in an integrated mode, can integrate the dynamic magnetic therapy and the positioning physiotherapy function of the bionic convex module, and have a positive effect on improving the rehabilitation auxiliary treatment of the cervical and lumbar vertebra diseases.

This invention relates to the field of biomedical materials, providing non-denatured type II collagen ultrafine powder with cartilage tissue-targeted growth and structural repair functions, its bioactivity preservation preparation method, and its application in joints. The ultrafine powder has an average particle size of 0.5-50 μm, a triple helix structure integrity rate of not less than 85%, a thermal denaturation temperature of 38-48℃, and retains chondrocyte binding domains CB10, CB11, and MMP cleavage sites. The preparation method includes raw material pretreatment, time-limited enzymatic hydrolysis, graded purification, and ultra-low temperature ball milling. The product can be used for the repair and treatment of cartilage degenerative diseases such as osteoarthritis and cartilage damage.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

The present disclosure provides methods of treating, preventing, or delaying the onset of a late-onset neurodegenerative disease, e.g., Niemann-Pick type C, or a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of acetyl-leucine to the subject, wherein the subject is heterozygous NPC1 gene mutation carrier.

The present disclosure provides pharmaceutical compositions containing nucleic acid molecules encoding PEDF which are codon-optimized, as well as methods for increasing the level of PEDF in the treatment or prophylaxis of retinal degenerative diseases, such as age-related macular degeneration (AMD), or other neurodegenerative diseases.

The present invention relates to the provision of novel sources of microglia-like cells having a unique phenotype. In particular, the present invention relates to medical uses of such microglia-like cells, in particular in relation to treatment of neurodegenerative diseases.

The application discloses a neurodegenerative disease treatment composition and relates to the technical field of neurodegenerative disease treatment.The active ingredients of the composition include: exosomes secreted by neural stem cells, exosomes from ginseng, and exosomes from intestinal probiotics; wherein: the three kinds of exosomes exist in parallel, and are all formed by the common induction of traditional Chinese medicine active substance ginseng exosomes and intestinal probiotic fermentation liquor; after the neural stem cell exosomes are induced by the common induction of ginseng exosomes and intestinal probiotic fermentation liquor, the neurotrophic factors and regulatory RNA carried by the neural stem cell exosomes are both enhanced in content and functional activity, so that the neural repair and regulation capabilities are improved. The neural stem cell exosomes are induced by the common induction of ginseng exosomes and probiotic fermentation liquor, the neural repair, anti-inflammatory and antioxidant, and brain-gut axis regulation capabilities of the neural stem cell exosomes are enhanced. When the combined drug or stem cells are applied, the treatment effect and cell integration efficiency are improved, and a new scheme of synergistic precise treatment is provided for neurodegenerative diseases.

This disclosure relates to the use of glycogen phosphatase B agonists in the treatment of neurodegenerative diseases. Specifically, this disclosure provides the use of glycogen phosphatase B agonists (preferably adenosine monophosphate) in the preparation of medicaments for the prevention or treatment of neurodegenerative diseases. This disclosure demonstrates that glycogen phosphatase B agonists (AMPs) hold promise as a safe and effective treatment option for patients with neurodegenerative diseases.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

Described herein are compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 μM, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX / LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

The present invention relates to the treatment of neurodegenerative diseases, a group of chronic progressive disorders characterized by the gradual loss of neurons or neuronal function in discrete regions of the central nervous system (CNS). In particular, the present invention relates to alkaline phosphatase (AP) for use in the treatment or prevention of mammals suffering from or at risk of neurodegenerative disorders caused by reduced peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1) activity.

The application discloses an application of intervention of stress granule degradation by regulating TM9SF1 expression, and belongs to the technical field of biotechnology.It is found for the first time that TM9SF1 is a key molecule for regulating stress granule degradation, up-regulation of TM9SF1 expression can significantly promote stress granule degradation through an autophagy-lysosome pathway, and down-regulation of TM9SF1 expression will lead to stress granule degradation disorder and abnormal accumulation.The application also provides application of TM9SF1 in preparation of medicines for preventing, relieving or treating diseases (neurodegenerative diseases, malignant tumors, viral infectious diseases and the like) related to abnormal accumulation of stress granules, and a method for intervention of stress granule degradation.The application provides a new target for treatment of stress granule related diseases, has the advantages of strong targeting, wide application range, wide clinical conversion prospect and the like, and fills the blank of specific regulation of stress granule in the prior art.

The present disclosure provides cannabinoid drug substances, pharmaceutical compositions and methods of treating neurological or neurodegenerative disorders in a human patient.

The present invention pertains to the anti-inflammatory therapeutic effect of xantohumol in spinal cord injury (SCI). The continuous administration of xanthohumol for 1-8 weeks to SCI rats resulted in improved results in 4 clinical tests used and in lowering and faster elimination of macrophages from the SCI lesion. Since the infiltration of the SCI lesion by numerous phagocytic macrophages indicates a severe destructive inflammation of extraordinary longevity, administration of xanthohumol is neuroprotective and resulted in a better and faster recovery of the locomotor function and the strength and sensory function in the hind limbs, in a shorter period of paralysis of the urinary bladder and in the recovery of the body weight lost due to the SCI surgery. Since the traumatic brain injury (TBI) involving the white matter, and stroke involving the white matter initiate the severe destructive inflammation as in the SCI, the administration of xanthohumol is expected to be anti-inflammatory and neuroprotective in both brain diseases. Since neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and Parkinson's disease, immune mediated neuroinflammation including multiple sclerosis and neuromyelitis optica and cerebrospinal infections have inflammatory pathogenesis involving microgliosis and infiltration by macrophages, the administration of xanthohumol is expected to result in therapeutic inhibition of progression of all above diseases as well as of related neurodegenerative, immune mediated and infectious diseases of the brain and of the spinal cord.

Provided herein are compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which are used for inhibition of SARM1 proteins, as well as compositions comprising these compounds and methods of treatment by their administration.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

Methods and compositions for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARα expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction. Also provided are methods of treating peripheral metabolic dysfunction associated with neurodegenerative conditions.

The application discloses a lumbar degenerative disease patient treatment expectation evaluation system and relates to the technical field of medical health information processing; the system comprises a data acquisition unit, a expectation evaluation unit, an influence factor analysis unit and a report generation unit; the data acquisition unit is used for collecting multidimensional information of a lumbar degenerative disease patient; the expectation evaluation unit is connected with the data acquisition unit and is used for quantitatively evaluating the treatment expectation of the patient based on the collected information; the influence factor analysis unit is connected with the expectation evaluation unit and is used for analyzing key factors influencing the treatment expectation of the patient; the report generation unit is connected with the expectation evaluation unit and the influence factor analysis unit and is used for integrating evaluation and analysis results and generating a visual evaluation report. The application integrates various evaluation tools that have been tested for reliability and validity, converts subjective inquiries that are originally scattered and depend on the personal experience of medical staff into a unified, standardized and multidimensional quantitative evaluation process, and ensures the scientificity and comparability of evaluation results.